Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to $72000.0.

  • Pliant Therapeutics' Cash from Financing Activities fell 8674.03% to $72000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $672000.0, marking a year-over-year decrease of 9710.77%. This contributed to the annual value of $23.1 million for FY2024, which is 9157.56% down from last year.
  • Pliant Therapeutics' Cash from Financing Activities amounted to $72000.0 in Q3 2025, which was down 8674.03% from $498000.0 recorded in Q1 2025.
  • Over the past 5 years, Pliant Therapeutics' Cash from Financing Activities peaked at $273.3 million during Q1 2023, and registered a low of -$153000.0 during Q1 2022.
  • Its 5-year average for Cash from Financing Activities is $29.3 million, with a median of $507000.0 in 2021.
  • In the last 5 years, Pliant Therapeutics' Cash from Financing Activities plummeted by 11116.79% in 2022 and then soared by 17874444.44% in 2023.
  • Over the past 5 years, Pliant Therapeutics' Cash from Financing Activities (Quarter) stood at $516000.0 in 2021, then tumbled by 44.96% to $284000.0 in 2022, then decreased by 22.89% to $219000.0 in 2023, then crashed by 53.42% to $102000.0 in 2024, then dropped by 29.41% to $72000.0 in 2025.
  • Its Cash from Financing Activities stands at $72000.0 for Q3 2025, versus $498000.0 for Q1 2025 and $102000.0 for Q4 2024.